Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT03794349 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

94

Enrollment

NETWORK

Sponsor class

Conditions

High Risk Neuroblastoma
Recurrent Neuroblastoma
Refractory Neuroblastoma

Interventions

BIOLOGICAL: Dinutuximab
DRUG: Eflornithine Hydrochloride
DRUG: Irinotecan Hydrochloride
BIOLOGICAL: Sargramostim
DRUG: Temozolomide

Sponsor

Children's Oncology Group

Collaborators

[object Object]